Results 221 to 230 of about 81,769 (261)
Some of the next articles are maybe not open access.
Expert Opinion on Pharmacotherapy, 2007
Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming the lives of patients within a median of 1 year after diagnosis. Treatment of GBM requires a multidisciplinary approach. Treatments include surgery, radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an active agent against malignant gliomas.
Tomokazu, Aoki +2 more
openaire +2 more sources
Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming the lives of patients within a median of 1 year after diagnosis. Treatment of GBM requires a multidisciplinary approach. Treatments include surgery, radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an active agent against malignant gliomas.
Tomokazu, Aoki +2 more
openaire +2 more sources
Science's STKE, 2004
The mechanism by which the tumor suppressor PTEN slows tumor cell migration is not well characterized. A recent study by Raftopoulou et al . shows that a lack of PTEN protein phosphatase activity accelerates the migration of glioblastoma cells.
Merlo, Adrian, Bettler, Bernhard
openaire +3 more sources
The mechanism by which the tumor suppressor PTEN slows tumor cell migration is not well characterized. A recent study by Raftopoulou et al . shows that a lack of PTEN protein phosphatase activity accelerates the migration of glioblastoma cells.
Merlo, Adrian, Bettler, Bernhard
openaire +3 more sources
The American Journal of the Medical Sciences, 1980
Glioblastoma multiforme is the most common primary brain tumor of adults, as well as the most malignant. Its etiology is unknown, but the tumor is thought to arise through dedifferentiation of adult astrocytes. It occurs most frequently between the ages of 40 and 60, in men more often than in women (1.5:1).
openaire +2 more sources
Glioblastoma multiforme is the most common primary brain tumor of adults, as well as the most malignant. Its etiology is unknown, but the tumor is thought to arise through dedifferentiation of adult astrocytes. It occurs most frequently between the ages of 40 and 60, in men more often than in women (1.5:1).
openaire +2 more sources
Anti-Cancer Agents in Medicinal Chemistry, 2015
This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 ...
openaire +2 more sources
This article focuses on the possible application of antagonists of the G-protein coupled chemokine receptor, CXCR4, for the treatment of glioblastoma and summarises the evidence for CXCR4 antagonism being a viable therapeutic approach. Particular attention is paid to the role of this receptor in cancer stem cell biology, and the maintenance of CXCR4 ...
openaire +2 more sources
Gériatrie et Psychologie Neuropsychiatrie du Viellissement, 2011
The incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors for gliomas, and the optimal management of this population remains largely unsettled because older patients are often excluded from clinical trials.
Florence, Laigle-Donadey +1 more
openaire +2 more sources
The incidence of malignant gliomas is growing in the elderly population. Unfortunately, increasing age is one of the most important negative prognostic factors for gliomas, and the optimal management of this population remains largely unsettled because older patients are often excluded from clinical trials.
Florence, Laigle-Donadey +1 more
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2008
Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors.
Brandes AA +5 more
openaire +3 more sources
Glioblastoma (GBM) is the most malignant among astrocytic tumours and is associated with a poor prognosis. Age, performance status, mini-mental status examination score, methylation status of methylguanine methyltransferase promoter and extent of surgery constitute the main prognostic factors.
Brandes AA +5 more
openaire +3 more sources
World Neurosurgery, 2018
Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor ...
Jessica A, Wilcox +2 more
openaire +2 more sources
Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor ...
Jessica A, Wilcox +2 more
openaire +2 more sources
Current Treatment Options in Neurology, 2009
Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide.
Mary, Welch, Rose, Lai
openaire +2 more sources
Optimal management of newly diagnosed glioblastoma multiforme includes maximal surgical resection, followed by 60 Gy of external beam radiation plus concomitant daily temozolomide and at least six additional monthly cycles of maintenance temozolomide.
Mary, Welch, Rose, Lai
openaire +2 more sources
Immunotherapies continue to hold promise for the treatment of glioblastoma, a malignant central nervous system tumor. Thus far, success utilizing this approach has been limited. Negative trials with vaccines and immune checkpoint inhibitors have been unable to demonstrate improvement in survival, however, they have provided insights into hurdles which ...
Andrew, Williams, Rimas V, Lukas
openaire +2 more sources
Andrew, Williams, Rimas V, Lukas
openaire +2 more sources
Current Treatment Options in Neurology, 2008
Patients with newly diagnosed glioblastoma multiforme should undergo a maximal tumor resection and then, whenever possible, should be entered into a clinical trial. The current standard of care consists of external beam irradiation, to a total of 60 Gy over 6 weeks, in combination with low-dose daily temozolomide, followed by at least six cycles of ...
openaire +2 more sources
Patients with newly diagnosed glioblastoma multiforme should undergo a maximal tumor resection and then, whenever possible, should be entered into a clinical trial. The current standard of care consists of external beam irradiation, to a total of 60 Gy over 6 weeks, in combination with low-dose daily temozolomide, followed by at least six cycles of ...
openaire +2 more sources